SCHEMBL4738486

SCHEMBL4738486

COC1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC[C@H]([C@H](C)CCCC(C)C)[C@@]4(C)CC[C@@H]32)C1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP46A1 Q9Y6A2 2/20 0.77
POLA1 P09884 1/20 0.76
OSBP P22059 4/20 0.75
RORC P51449 3/20 0.75
USP2 O75604 2/20 0.75
OSBP2 Q969R2 2/20 0.75
LMNA P02545 1/20 0.75
ABCB1 P08183 1/20 0.75
ACHE P22303 1/20 0.69
EBP Q15125 1/20 0.69
DHCR7 Q9UBM7 1/20 0.69
GRIN1 Q05586 2/20 0.64
GRIN2A Q12879 2/20 0.64
NR1H3 Q13133 3/20 0.64
GBA1 P04062 2/20 0.63
UGCG Q16739 2/20 0.63
GBA2 Q9HCG7 2/20 0.63
NPC1L1 Q9UHC9 3/20 0.61
CRYAB P02511 1/20 0.61
HMGCR P04035 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20459397 1.00 CYP46A1 (0.77) CYP46A1POLA1OSBPRORCUSP2
SCHEMBL22013894 1.00 CYP46A1 (0.77) CYP46A1POLA1OSBPRORCUSP2
SCHEMBL15150903 1.00 CYP46A1 (0.77) CYP46A1POLA1OSBPRORCUSP2
SCHEMBL17663640 1.00 CYP46A1 (0.77) CYP46A1POLA1OSBPRORCUSP2
SCHEMBL12940685 1.00 CYP46A1 (0.77) CYP46A1POLA1OSBPRORCUSP2
SCHEMBL24405093 1.00 CYP46A1 (0.77) CYP46A1POLA1OSBPRORCUSP2
SCHEMBL20924867 1.00 CYP46A1 (0.77) CYP46A1POLA1OSBPRORCUSP2
SCHEMBL22389093 1.00 CYP46A1 (0.77) CYP46A1POLA1OSBPRORCUSP2
SCHEMBL21707464 1.00 CYP46A1 (0.77) CYP46A1POLA1OSBPRORCUSP2
SCHEMBL12896265 1.00 CYP46A1 (0.77) CYP46A1POLA1OSBPRORCUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115286676-B Synthesis method for preparing cholesterol methyl ether from diosgenin 沈阳化工研究院有限公司 2023-07-07 CN claimed
CN-115286676-A Synthetic method for preparing cholesterol methyl ether from diosgenin 沈阳化工研究院有限公司 2022-11-04 CN claimed
CN-109701028-A D configuration T7 peptide modified matrix material, wherein mesosome, drug delivery system and their preparation method and purposes 四川大学 2019-05-03 CN claimed
EP-4628893-A2 COMPOSITIONS AND METHODS FOR REMOVING INTERFERING SUBSTANCES Siemens Healthcare Diagnostics, Inc. (US) 2025-10-08 EP disclosed
EP-3856149-B1 COMPOSITIONS AND METHODS FOR REMOVING INTERFERING SUBSTANCES SIEMENS HEALTHCARE DIAGNOSTICS INC (US) 2025-07-30 EP disclosed
US-20250138001-A1 Liposome-containing Diagnostic Reagents and Methods of Production and Use Thereof SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2025-05-01 US disclosed
US-20250102404-A1 COMPOSITIONS AND METHODS FOR REMOVING INTERFERING SUBSTANCES SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2025-03-27 US disclosed
US-12203831-B2 Compositions and methods for removing interfering substances SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2025-01-21 US disclosed
EP-4490519-A1 LIPOSOME-CONTAINING DIAGNOSTIC REAGENTS AND METHODS OF PRODUCTION AND USE THEREOF Siemens Healthcare Diagnostics, Inc. (US) 2025-01-15 EP disclosed
CN-118901013-A Diagnostic agents containing liposomes, methods of production and uses thereof 美国西门子医学诊断股份有限公司 2024-11-05 CN disclosed
US-11918770-B2 Implants for localized drug delivery and methods of use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-03-05 US disclosed
WO-1995002424-A1 LOCALIZATION AND THERAPY OF NON-PROSTATIC ENDOCRINE CANCER WITH AGENTS DIRECTED AGAINST PROSTATE SPECIFIC ANTIGEN NORDION INTERNATIONAL INC. (CA) 1995-01-26 WO disclosed
US-4929603-A ANTICHOLESTEROL AGENTS, CARDIOVASCULAR DISORDERS ROOPERAL (NA) NV 1990-05-29 US disclosed
EP-0151385-B1 USE OF PHYTOSTEROLGLYCOSIDES FOR THE PREPARATION OF MEDICAMENTS FOR TREATMENT OF ELEVATED 5(6)ALPHA-EPOXYCHOLESTEROL LEVELS ROOPEROL (NA) NV (NL) 1989-04-19 EP disclosed
EP-0151385-A2 Use of phytosterolglycosides for the preparation of medicaments for treatment of elevated 5(6)alpha-epoxycholesterol levels ROOPEROL (NA) NV (NL) 1985-08-14 EP disclosed
EP-0077555-B1 METHOD FOR THE PURIFICATION OF CHOLESTEROL OXIDASE EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1985-08-07 EP disclosed
EP-0077555-A2 Method for the purification of cholesterol oxidase EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1983-04-27 EP disclosed
US-4374930-A ADSORPTION ON STEROID, ELUTION, SURFACTANT EASTMAN KODAK COMPANY (US) 1983-02-22 US disclosed
US-4170518-A Microbiological conversion of sterol derivatives to 5-androsten-17-one derivatives and their use SCHERING AKTIENGESELLSCHAFT (DE) 1979-10-09 US disclosed
US-3975287-A Liquid crystal composition for electric field indication KANSAI PAINT COMPANY, LTD. (JA) 1976-08-17 US disclosed